Pharmaceutical

Hong Kong approves Leqembi for Alzheimer’s treatment

BioArctic has announced that its partner, Eisai has approval from Hong Kong's Department of Health for Leqembi for the treatment of AD.

Jul 12, 2024 - 04:00
Hong Kong approves Leqembi for Alzheimer’s treatment
BioArctic has announced that its partner, Eisai has approval from Hong Kong's Department of Health for Leqembi for the treatment of AD.
Read the original article

Tags:

Previous Article

Biotech survey highlights where industry can focus for a thriving future  

Next Article

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Key Senate panel to consider PBM, drug pricing reform package

STAT+: Key Senate panel to consider PBM, drug pricing r...

Nov 3, 2023

Laurus Labs and IIT Kanpur partner for new gene therapy products

Laurus Labs and IIT Kanpur partner for new gene therapy...

Jun 19, 2023

Opinion: CMS must protect access to the ‘gold standard of breast reconstruction’

Opinion: CMS must protect access to the ‘gold standard ...

Jun 30, 2023